One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

BofA Securities maintained a Buy rating on Eli Lilly stock (NYSE:LLY), with a price target set at $997.00. With a market capitalization of $706 billion and impressive revenue growth of 27.4% over the ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

We recently published a list of 12 Stocks That Could Split in the Near Future. In this article, we are going to take a look ...

Eli Lilly and Company ( NYSE:LLY ) will increase its dividend from last year's comparable payment on the 10th of ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...